{"entity":{"type":"insider","cik":"0001589725","url":"/insider/0001589725","json_url":"/insider/0001589725.json","name":"Thackray Helen M.","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":14,"n_filings":11,"first":"2016-07-06","last":"2024-05-15","span_basis":"filed_date"},"name_variants":[{"name":"Thackray Helen M.","source":"filing","n_filings":11,"first_seen":"2016-07-06","last_seen":"2024-05-15"}],"transactions":[{"id":2347368,"accession":"0001127602-24-015371","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001127602-24-015371","line_url":"/filing/0001127602-24-015371#line-1","is_derivative":false,"issuer_cik":"0000882796","issuer_name":"BIOCRYST PHARMACEUTICALS INC","issuer_ticker":"BCRX","issuer_name_source":null,"issuer_url":"/issuer/0000882796","owner_cik":"0001589725","owner_name":"Thackray Helen M.","owner_display_name":"Thackray Helen M.","owner_url":"/insider/0001589725","role":"Officer (Chief R&D Officer)","role_mark":"O","role_mark_label":"Officer (Chief R&D Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief R&D Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":30000.0,"shares_display":"30,000","price_per_share":5.86,"price_display":"5.86","price_state":"stated","total_value":175800.0,"total_display":"175,800.00","total_whole":"175,800","shares_owned_after":272139.0,"shares_owned_after_display":"272,139","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-05-14","filed_date":"2024-05-15","scope":"insider"},{"id":8120601,"accession":"0001127602-23-012587","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001127602-23-012587","line_url":"/filing/0001127602-23-012587#line-1","is_derivative":false,"issuer_cik":"0000882796","issuer_name":"BIOCRYST PHARMACEUTICALS INC","issuer_ticker":"BCRX","issuer_name_source":null,"issuer_url":"/issuer/0000882796","owner_cik":"0001589725","owner_name":"Thackray Helen M.","owner_display_name":"Thackray Helen M.","owner_url":"/insider/0001589725","role":"Officer (Chief R&D Officer)","role_mark":"O","role_mark_label":"Officer (Chief R&D Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief R&D Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7000.0,"shares_display":"7,000","price_per_share":8.29,"price_display":"8.29","price_state":"stated","total_value":58030.0,"total_display":"58,030.00","total_whole":"58,030","shares_owned_after":207275.0,"shares_owned_after_display":"207,275","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-04-03","filed_date":"2023-04-05","scope":"insider"},{"id":6604544,"accession":"0001127602-22-027887","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001127602-22-027887","line_url":"/filing/0001127602-22-027887#line-1","is_derivative":false,"issuer_cik":"0000882796","issuer_name":"BIOCRYST PHARMACEUTICALS INC","issuer_ticker":"BCRX","issuer_name_source":null,"issuer_url":"/issuer/0000882796","owner_cik":"0001589725","owner_name":"Thackray Helen M.","owner_display_name":"Thackray Helen M.","owner_url":"/insider/0001589725","role":"Officer (Chief R&D Officer)","role_mark":"O","role_mark_label":"Officer (Chief R&D Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief R&D Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3125.0,"shares_display":"3,125","price_per_share":10.89,"price_display":"10.89","price_state":"stated","total_value":34031.25,"total_display":"34,031.25","total_whole":"34,031","shares_owned_after":133275.0,"shares_owned_after_display":"133,275","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-12-15","filed_date":"2022-12-19","scope":"insider"},{"id":6929542,"accession":"0001127602-22-011188","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001127602-22-011188","line_url":"/filing/0001127602-22-011188#line-1","is_derivative":false,"issuer_cik":"0000882796","issuer_name":"BIOCRYST PHARMACEUTICALS INC","issuer_ticker":"BCRX","issuer_name_source":null,"issuer_url":"/issuer/0000882796","owner_cik":"0001589725","owner_name":"Thackray Helen M.","owner_display_name":"Thackray Helen M.","owner_url":"/insider/0001589725","role":"Officer (Chief R&D Officer)","role_mark":"O","role_mark_label":"Officer (Chief R&D Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief R&D Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7600.0,"shares_display":"7,600","price_per_share":16.2,"price_display":"16.20","price_state":"stated","total_value":123120.0,"total_display":"123,120.00","total_whole":"123,120","shares_owned_after":136400.0,"shares_owned_after_display":"136,400","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-04-01","filed_date":"2022-04-04","scope":"insider"},{"id":4198858,"accession":"0001209191-17-065185","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-17-065185","line_url":"/filing/0001209191-17-065185#line-1","is_derivative":false,"issuer_cik":"0001253689","issuer_name":"GLYCOMIMETICS INC","issuer_ticker":"GLYC","issuer_name_source":null,"issuer_url":"/issuer/0001253689","owner_cik":"0001589725","owner_name":"Thackray Helen M.","owner_display_name":"Thackray Helen M.","owner_url":"/insider/0001589725","role":"Officer (SVP Clinical Development, CMO)","role_mark":"O","role_mark_label":"Officer (SVP Clinical Development, CMO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP Clinical Development, CMO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2000.0,"shares_display":"2,000","price_per_share":15.01,"price_display":"15.01","price_state":"stated","total_value":30020.0,"total_display":"30,020.00","total_whole":"30,020","shares_owned_after":148615.0,"shares_owned_after_display":"148,615","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-12-08","filed_date":"2017-12-12","scope":"insider"},{"id":5254786,"accession":"0001209191-17-053214","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-17-053214","line_url":"/filing/0001209191-17-053214#line-1","is_derivative":false,"issuer_cik":"0001253689","issuer_name":"GLYCOMIMETICS INC","issuer_ticker":"GLYC","issuer_name_source":null,"issuer_url":"/issuer/0001253689","owner_cik":"0001589725","owner_name":"Thackray Helen M.","owner_display_name":"Thackray Helen M.","owner_url":"/insider/0001589725","role":"Officer (SVP Clinical Development, CMO)","role_mark":"O","role_mark_label":"Officer (SVP Clinical Development, CMO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP Clinical Development, CMO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2000.0,"shares_display":"2,000","price_per_share":13.0,"price_display":"13.00","price_state":"stated","total_value":26000.0,"total_display":"26,000.00","total_whole":"26,000","shares_owned_after":150615.0,"shares_owned_after_display":"150,615","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-09-18","filed_date":"2017-09-18","scope":"insider"},{"id":4905110,"accession":"0001209191-17-036114","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-17-036114","line_url":"/filing/0001209191-17-036114#line-1","is_derivative":false,"issuer_cik":"0001253689","issuer_name":"GLYCOMIMETICS INC","issuer_ticker":"GLYC","issuer_name_source":null,"issuer_url":"/issuer/0001253689","owner_cik":"0001589725","owner_name":"Thackray Helen M.","owner_display_name":"Thackray Helen M.","owner_url":"/insider/0001589725","role":"Officer (SVP Clinical Development, CMO)","role_mark":"O","role_mark_label":"Officer (SVP Clinical Development, CMO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP Clinical Development, CMO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2000.0,"shares_display":"2,000","price_per_share":15.57,"price_display":"15.57","price_state":"stated","total_value":31140.0,"total_display":"31,140.00","total_whole":"31,140","shares_owned_after":152615.0,"shares_owned_after_display":"152,615","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-05-25","filed_date":"2017-05-30","scope":"insider"},{"id":4831348,"accession":"0001209191-17-034534","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-17-034534","line_url":"/filing/0001209191-17-034534#line-1","is_derivative":false,"issuer_cik":"0001253689","issuer_name":"GLYCOMIMETICS INC","issuer_ticker":"GLYC","issuer_name_source":null,"issuer_url":"/issuer/0001253689","owner_cik":"0001589725","owner_name":"Thackray Helen M.","owner_display_name":"Thackray Helen M.","owner_url":"/insider/0001589725","role":"Officer (SVP Clinical Development, CMO)","role_mark":"O","role_mark_label":"Officer (SVP Clinical Development, CMO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP Clinical Development, CMO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2000.0,"shares_display":"2,000","price_per_share":12.14,"price_display":"12.14","price_state":"stated","total_value":24280.0,"total_display":"24,280.00","total_whole":"24,280","shares_owned_after":154615.0,"shares_owned_after_display":"154,615","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-05-19","filed_date":"2017-05-22","scope":"insider"},{"id":2478568,"accession":"0001209191-16-144211","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-16-144211","line_url":"/filing/0001209191-16-144211","is_derivative":false,"issuer_cik":"0001253689","issuer_name":"GLYCOMIMETICS INC","issuer_ticker":"GLYC","issuer_name_source":null,"issuer_url":"/issuer/0001253689","owner_cik":"0001589725","owner_name":"Thackray Helen M.","owner_display_name":"Thackray Helen M.","owner_url":"/insider/0001589725","role":"Officer (VP Clinical Development, CMO)","role_mark":"O","role_mark_label":"Officer (VP Clinical Development, CMO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"VP Clinical Development, CMO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4000.0,"shares_display":"4,000","price_per_share":7.00025,"price_display":"7.00","price_state":"stated","total_value":28001.0,"total_display":"28,001.00","total_whole":"28,001","shares_owned_after":156715.0,"shares_owned_after_display":"156,715","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-10-03","filed_date":"2016-10-04","scope":"insider","n_lines":2},{"id":2739240,"accession":"0001209191-16-133630","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-16-133630","line_url":"/filing/0001209191-16-133630#line-1","is_derivative":false,"issuer_cik":"0001253689","issuer_name":"GLYCOMIMETICS INC","issuer_ticker":"GLYC","issuer_name_source":null,"issuer_url":"/issuer/0001253689","owner_cik":"0001589725","owner_name":"Thackray Helen M.","owner_display_name":"Thackray Helen M.","owner_url":"/insider/0001589725","role":"Officer (VP Clinical Development, CMO)","role_mark":"O","role_mark_label":"Officer (VP Clinical Development, CMO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"VP Clinical Development, CMO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2000.0,"shares_display":"2,000","price_per_share":8.0,"price_display":"8.00","price_state":"stated","total_value":16000.0,"total_display":"16,000.00","total_whole":"16,000","shares_owned_after":160615.0,"shares_owned_after_display":"160,615","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-07-20","filed_date":"2016-07-21","scope":"insider"},{"id":2130652,"accession":"0001209191-16-131738","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-16-131738","line_url":"/filing/0001209191-16-131738#line-3","is_derivative":false,"issuer_cik":"0001253689","issuer_name":"GLYCOMIMETICS INC","issuer_ticker":"GLYC","issuer_name_source":null,"issuer_url":"/issuer/0001253689","owner_cik":"0001589725","owner_name":"Thackray Helen M.","owner_display_name":"Thackray Helen M.","owner_url":"/insider/0001589725","role":"Officer (VP Clinical Development, CMO)","role_mark":"O","role_mark_label":"Officer (VP Clinical Development, CMO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"VP Clinical Development, CMO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6796.0,"shares_display":"6,796","price_per_share":6.68,"price_display":"6.68","price_state":"stated","total_value":45397.28,"total_display":"45,397.28","total_whole":"45,397","shares_owned_after":162615.0,"shares_owned_after_display":"162,615","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-07-06","filed_date":"2016-07-06","scope":"insider"},{"id":2130649,"accession":"0001209191-16-131738","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-16-131738","line_url":"/filing/0001209191-16-131738#line-2","is_derivative":false,"issuer_cik":"0001253689","issuer_name":"GLYCOMIMETICS INC","issuer_ticker":"GLYC","issuer_name_source":null,"issuer_url":"/issuer/0001253689","owner_cik":"0001589725","owner_name":"Thackray Helen M.","owner_display_name":"Thackray Helen M.","owner_url":"/insider/0001589725","role":"Officer (VP Clinical Development, CMO)","role_mark":"O","role_mark_label":"Officer (VP Clinical Development, CMO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"VP Clinical Development, CMO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10136.0,"shares_display":"10,136","price_per_share":7.01,"price_display":"7.01","price_state":"stated","total_value":71053.36,"total_display":"71,053.36","total_whole":"71,053","shares_owned_after":169411.0,"shares_owned_after_display":"169,411","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-07-05","filed_date":"2016-07-06","scope":"insider"},{"id":2130644,"accession":"0001209191-16-131738","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-16-131738","line_url":"/filing/0001209191-16-131738#line-1","is_derivative":false,"issuer_cik":"0001253689","issuer_name":"GLYCOMIMETICS INC","issuer_ticker":"GLYC","issuer_name_source":null,"issuer_url":"/issuer/0001253689","owner_cik":"0001589725","owner_name":"Thackray Helen M.","owner_display_name":"Thackray Helen M.","owner_url":"/insider/0001589725","role":"Officer (VP Clinical Development, CMO)","role_mark":"O","role_mark_label":"Officer (VP Clinical Development, CMO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"VP Clinical Development, CMO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5068.0,"shares_display":"5,068","price_per_share":7.4,"price_display":"7.40","price_state":"stated","total_value":37503.2,"total_display":"37,503.20","total_whole":"37,503","shares_owned_after":179547.0,"shares_owned_after_display":"179,547","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-07-01","filed_date":"2016-07-06","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":14,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":1,"open_market":true},{"code":"S","label":"Open-market sale","n":13,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":14},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0000882796","name":"BIOCRYST PHARMACEUTICALS INC","url":"/issuer/0000882796","role":"Officer (Chief R&D Officer)","n_filings":4,"first_seen":"2022-04-04","last_seen":"2024-05-15"},{"type":"issuer","type_label":"ISSUER","cik":"0001253689","name":"GLYCOMIMETICS INC","url":"/issuer/0001253689","role":"Officer (SVP Clinical Development, CMO)","n_filings":7,"first_seen":"2016-07-06","last_seen":"2017-12-12"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001589725","retrieved_at":"2026-08-24T18:27:56+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}